Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
63.940USD
-1.140-1.75%
Close 09-18 16:00（ET）
12.39BMarket Cap
45.89P/E TTM
BioMarin Pharmaceutical Inc (BMRN) Revenue Performance
Updated: Jun 30, 2026Last year, BioMarin Pharmaceutical Inc generated 926.92M USD for its biggest-performing segment, Voxzogo. The United States made the largest contribution, accounting for 1.10B USD last year. For the latest quarter, BioMarin Pharmaceutical Inc reported the revenue of 252.53M USD for the period ending 2026-06-30, which came from the top-performing segment, Voxzogo. United States contributed the highest revenue, at 371.07M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Voxzogo
Vimizim
Naglazyme
Palynziq
Aldurazyme
Brineura
Kuvan
Royalty and other revenue
Roctavian
Firdapse
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Voxzogo
926.92M(28.78%)
735.09M(25.76%)
469.88M(19.42%)
169.13M(8.28%)
5.86M(0.33%)
--(--)
--(--)
--(--)
Vimizim
792.05M(24.59%)
739.78M(25.92%)
701.05M(28.98%)
663.74M(32.50%)
623.14M(34.94%)
544.26M(30.14%)
544.35M(32.77%)
481.98M(32.78%)
Naglazyme
485.40M(15.07%)
479.58M(16.80%)
420.29M(17.37%)
443.79M(21.73%)
380.45M(21.33%)
391.30M(21.67%)
374.33M(22.54%)
345.85M(23.52%)
Palynziq
433.31M(13.45%)
355.05M(12.44%)
303.92M(12.56%)
255.03M(12.49%)
237.47M(13.32%)
170.98M(9.47%)
86.86M(5.23%)
12.17M(0.83%)
Aldurazyme
208.51M(6.47%)
183.89M(6.44%)
131.25M(5.43%)
128.42M(6.29%)
122.77M(6.88%)
130.11M(7.20%)
97.81M(5.89%)
135.10M(9.19%)
Brineura
186.40M(5.79%)
169.08M(5.92%)
161.89M(6.69%)
154.33M(7.56%)
128.03M(7.18%)
110.19M(6.10%)
72.00M(4.33%)
39.89M(2.71%)
Kuvan
99.53M(3.09%)
120.90M(4.24%)
180.77M(7.47%)
227.58M(11.14%)
285.78M(16.02%)
457.74M(25.35%)
463.35M(27.90%)
433.58M(29.49%)
Royalty and other revenue
53.49M(1.66%)
44.47M(1.56%)
46.69M(1.93%)
--(--)
--(--)
--(--)
--(--)
--(--)
Roctavian
35.64M(1.11%)
26.07M(0.91%)
3.49M(0.14%)
--(--)
--(--)
--(--)
--(--)
--(--)
Firdapse
--(--)
--(--)
--(--)
--(--)
--(--)
1.29M(0.07%)
22.35M(1.35%)
21.79M(1.48%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
Europe
Rest of the world
Latin America
ALDURAZYME net product revenues marked by Sanofi
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
1.10B(34.88%)
924.81M(32.92%)
771.31M(32.51%)
684.28M(35.76%)
657.70M(36.88%)
912.38M(49.04%)
778.44M(45.68%)
696.79M(46.73%)
Europe
874.33M(27.60%)
829.03M(29.51%)
669.33M(28.21%)
650.95M(34.02%)
558.95M(31.34%)
518.47M(27.87%)
509.19M(29.88%)
436.43M(29.27%)
Rest of the world
544.47M(17.19%)
493.63M(17.57%)
468.21M(19.73%)
311.57M(16.28%)
375.69M(21.07%)
223.75M(12.03%)
197.63M(11.60%)
172.94M(11.60%)
Latin America
435.48M(13.75%)
378.08M(13.46%)
332.44M(14.01%)
266.80M(13.94%)
191.15M(10.72%)
205.86M(11.07%)
218.79M(12.84%)
185.05M(12.41%)
ALDURAZYME net product revenues marked by Sanofi
208.51M(6.58%)
183.89M(6.55%)
131.25M(5.53%)
--(--)
--(--)
--(--)
--(--)
--(--)